Drug

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo
Clinical trial resultsNASDAQ: REGN

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive 84‑week results from the Phase 3 OPTIMA trial evaluating Pasatru (garetosmab‑grts) in adults with fibrodysplasia ossificans progressiva (FOP) – a rare, debilitating genetic…

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn's Disease – 35.8% Achieved Endoscopic Remission

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn’s Disease – 35.8% Achieved Endoscopic Remission

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
J&J's Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases
J&JJohnson & Johnson

J&J’s Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases

Asieris Pharma's Cevira Wins NMPA Approval – World's First Non‑Surgical Photodynamic Therapy for Cervical Lesions
Asieris PharmaceuticalsProduct approvals

Asieris Pharma’s Cevira Wins NMPA Approval – World’s First Non‑Surgical Photodynamic Therapy for Cervical Lesions

AntengeneEBR: UCB

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

Clinical trial approval / initiationHKG: 1541

ImmuneOnco’s IMM0306S Wins NMPA Approval – Subcutaneous CD47×CD20 Bispecific for Lupus Enters Clinic

Show More